60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
Часто задаваемые вопросы
В каком секторе работает 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)?
60 Degrees Pharmaceuticals, Inc. Common Stock относится к сектору Здравоохранение.
Какова текущая цена акций 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)?
По последним данным, цена акций 60 Degrees Pharmaceuticals, Inc. Common Stock составляет 0,87 $, предыдущее закрытие — 0,87 $. За последнюю торговую сессию акции 60 Degrees Pharmaceuticals, Inc. Common Stock снизились на -0,00 $, что соответствует падению на -0,25%.
Выплачивает ли 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) дивиденды?
Нет, 60 Degrees Pharmaceuticals, Inc. Common Stock не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)?
У компании 60 Degrees Pharmaceuticals, Inc. Common Stock бета 2.541, что свидетельствует о крайне высокой волатильности по сравнению с рынком
